Christian Borel

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

Thierry Petit, M. Wilt, Michel Velten et al. · European Journal of Cancer · 2003 · 272 citations

Breast Oncology, Breast Cancer Patients, Medicine +9

Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer

C Jacquillat, Marise Weil, F Baillet et al. · Cancer · 1990 · 261 citations · Full text

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Jean Bourhis, Fernando Rivera, Ahmad Awada et al. · Journal of Clinical Oncology · 2006 · 172 citations

Phase I/ii Study, Medicine, Pharmacology +10

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.

D. Khayat, Christian Borel, J.M. Tourani et al. · Journal of Clinical Oncology · 1993 · 149 citations